Protein A is the gold standard for Mab capture. For Mab-X, the team loads clarified harvest at 400 cm/h onto a MabSelect PrismA column.
Due to the relatively high pI of the mAb (≈9.3), CEX was highly effective at binding the product while allowing impurities to pass, or using gradient elution to separate the main monomer peak from acidic/basic variants. 4. Analytical Strategies and Quality by Design (QbD)
No bioprocess case study is complete without analytics. The Mab-X team implements a real-time process analytical technology (PAT) framework:
: It demonstrates how to use systematic risk assessments (like FMEA) to justify process parameters and ranges.
Even after Protein A, impurities remain. We implemented a two-step polishing phase: A Mab A Case Study In Bioprocess Development
The step achieved a turbidity reduction to < 10 NTU and a step yield of 92%, protecting the downstream Protein A column from fouling. 3. Downstream Processing: Purification and Safety Assurance
2. Upstream Process Development: Cell Line and Culture Optimization
This case study demonstrates:
Run in binder-elute mode to separate charge variants (acidic and basic species) and drop HMW aggregates to Protein A is the gold standard for Mab capture
This case study demonstrates that a modern mAb process is not developed linearly. By integrating upstream media chemistry (clone #47B + metal modulation) with downstream flocculation and high-resilience Protein A capture, the team transformed a problematic, aggregate-prone mAb (initial yield <1.5 g/L recoverable) into a robust 6.1 g/L titer process with a 71% final recovery. The drug product met all Phase I release specifications for purity, potency, and safety.
This article presents a detailed case study of the development process for a humanized monoclonal antibody ("mAb A" or "the mAb"), focusing on the transition from early clone selection to the optimization of upstream cultivation and downstream purification strategies, emphasizing a Quality by Design (QbD) approach. 1. Project Background: Defining the Monoclonal Antibody
The case study provides detailed insights into both primary stages of production.
The study begins by defining the desired performance and safety of A-Mab, including its intended clinical use and dosage form. Even after Protein A, impurities remain
The polishing CEX step requires a 45 cm diameter column (Vantage VL). Packing at scale reveals a consistent "tilt" in the bed height. After four failed packs, the team switches to dynamic axial compression and reduces the slurry concentration from 50% to 35%, achieving a HETP (Height Equivalent to a Theoretical Plate) of <0.05.
Scale-up parameters remained consistent across three consecutive 500L verification runs, demonstrating high predictability. Conclusion
Once the mAb is produced, it must be isolated and purified from the cell culture. Contentstack A–Mab: A Case Study in Bioprocess Development - ISPE 30 Oct 2009 —